Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05522205

Regulated Cannabis Access in Basel

The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Cannabis Use Disorder Mental Disorders Mental Health Disorder Physical Illness

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Canton Basel-Stadt

Basel, Canton of Basel-City, Switzerland

About this study

This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample)

Exclusion criteria

  • pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment

Treatment and study plan

Regulated cannabis access in pharmacies

Other

The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.

Primary outcomes

  1. Change in problematic cannabis consumption behaviour

    Time frame: 6 / 12 /18 /24 / 30 months

    Cannabis Use Disorder Identification Test - Revised; min. value 0, max. value 32; higher scores mean worse outcome

Secondary outcomes

  1. Change in depression

    Time frame: 6 / 12 /18 /24 / 30 months

    Patient Health Questionnaire; min. value 0, max. value 27; higher scores mean worse outcome

  2. Change in anxiety

    Time frame: 6 / 12 /18 /24 / 30months

    Generalized Anxiety Disorder; min. value 0, max. value 21; higher scores mean worse outcome

  3. Change in psychosis

    Time frame: 6 / 12 /18 /24 / 30 months

    Checklist of early intervention; min. value 0, max. value 8; higher scores mean worse outcome

  4. Change in physical health

    Time frame: 6 / 12 /18 /24 / 30 months

    Symptom Checklist - 90, Somatization; min. value 0, max. value 48; higher scores mean worse outcome

Sponsors and collaborators

Lead sponsor

Health Department of the Canton of Basel-Stadt

Other Gov

Collaborators

  • Psychiatric Services Aargau AG
  • University Psychiatric Clinics Basel
  • University of Basel

Registry information

Official study title

WEED CARE - Randomized Controlled Study on Regulated Cannabis Access for Recreational Use in Pharmacies in Basel

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Aug 30, 2022
Registry last updated
Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.